ArticleClinical and experimental immunology2023

A novel monoclonal antibody with improved FcγR blocking ability demonstrated non-inferior efficacy compared to IVIG in cynomolgus monkey ITP model at considerably lower dose.

Yuko Nakajima-Kato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.